Central nervous system involvement in XXXX : clinical characteristics and comparison of intracranial and spinal metastatic groups.

@entity1 @entity772 @entity3 @entity157 @entity204
From January 1993 to December 2006 we analyzed the clinical characteristics of @entity1 with @entity157 ( @entity157 ) with central nervous system (CNS) @entity3 at the Kaohsiung Chang Gung Memorial Hospital, Taiwan. Forty-six @entity1 with @entity157 and CNS @entity3 were identified, of whom 36 had intracranial @entity3 and 10 had spinal @entity3 . The clinical presentations, laboratory data and imaging studies were collected and analyzed. The age at the time of @entity157 diagnosis ranged from 34 to 78 years; CNS @entity3 occurred between 0 and 85 months after diagnosis and @entity204 followed between 0 and 93 months later. The Glasgow @entity772 Scale (GCS) score at the time of CNS @entity3 ranged from 7 to 15 and the @entity1 -Pugh score at diagnosis of @entity157 ranged from 5 to 15. @entity1 with spinal @entity3 had a higher GCS score and lower @entity1 -Pugh score at diagnosis. None of the serum biochemical studies showed unique abnormalities. From the data currently available, intracranial @entity3 is the most common site of CNS @entity3 of @entity157 . Advances in treating and diagnosing @entity157 have improved @entity1 outcomes remarkably; however, CNS @entity3 continues to have a grave prognosis. Without a specific biomarker for predicting CNS involvement in @entity157 , a high index of suspicion for the diagnosis should be maintained, particularly in @entity157 areas such as Taiwan.
